West Pharmaceutical Services (WST) Operating Expenses (2009 - 2026)

West Pharmaceutical Services (WST) has 18 years of Operating Expenses data on file, last reported at $115.3 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 10.55% year-over-year to $115.3 million; the trailing twelve-month figure through Mar 2026 stood at $478.9 million (up 17.49% YoY), and the FY2025 full-year result was $467.9 million, up 14.79% from the prior year.
• Operating Expenses eased to $115.3 million in Q1 2026, from $128.8 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $128.8 million in Q4 2025 to a low of $79.9 million in Q3 2022.
• A 5-year average of $105.2 million and a median of $104.3 million in 2024 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses slipped 23.9% in 2022 and surged 31.91% in 2023, its largest moves.
• Tracing WST's Operating Expenses over 5 years: stood at $101.6 million in 2022, then rose by 6.69% to $108.4 million in 2023, then decreased by 4.24% to $103.8 million in 2024, then gained by 24.08% to $128.8 million in 2025, then decreased by 10.48% to $115.3 million in 2026.
• Business Quant data shows WST's Operating Expenses at $115.3 million in Q1 2026, $128.8 million in Q4 2025, and $119.8 million in Q3 2025.